IOV-2001

Third-Generation CAR T-Cell Therapy Shows Promise in Relapsed/Refractory CLL

5 months ago

• A phase 1/2 study of HD-CAR-1, a third-generation CAR T-cell therapy, demonstrates encouraging response rates in heavily pretreated CLL patients. • Six of nine patients (67%) achieved complete remission (CR) three months post-treatment, with 83% showing undetectable minimal residual disease. • With a median follow-up of 27 months, the progression-free survival rate was 30%, and achieving CR correlated with significantly longer PFS (P = .024). • The therapy showed a favorable safety profile, with only one case of grade 3 cytokine release syndrome and no neurotoxicity observed.

Third-Generation CAR T-Cell Therapy Shows Promise in Relapsed/Refractory CLL

Drug Development Updates